Special Report By David Barboza — The Wire After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows
Biotech By Adam Feuerstein A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know
Business By Elizabeth Cooney A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world
Biotech By Elizabeth Cooney Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it
Business By Elizabeth Cooney ‘One thing cancer patients don’t generally have is time’: New cancer research leader brings urgency to Sanofi
Biotech By Elizabeth Cooney Startup Spotlight: Aiming to speed precision cancer therapies to children
Special Report By Erin Brodwin and Casey Ross Two years of halting progress and high turnover preceded Atul Gawande’s exit as Haven CEO
Business By Casey Ross and Erin Brodwin Atul Gawande to depart as CEO of splashy health venture. Is it ‘a death knell’?
Special Report By Nicholas Florko and Damian Garde With remdesivir, Gilead finds itself at strategic crossroads, with its reputation (and far more) at stake
Business By Andrew Joseph Gilead’s remdesivir has seen success against the coronavirus. Now the company has to make enough to supply the world
Business By Andrew Joseph Patients, drug makers grapple with how to continue cancer trials during the coronavirus
Biotech By Adam Feuerstein Biogen delays Alzheimer’s drug filing to FDA, citing Covid-19, complexity of data analysis
Business By Andrew Joseph, Adam Feuerstein, Damian Garde and Matthew Herper Data for Gilead’s potential coronavirus therapy are coming soon. Here’s what you need to know
Biotech By Adam Feuerstein Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer
Business By Jonathan Saltzman — Boston Globe Boston Scientific cutting hours and pay as revenue drops
Biotech By Adam Feuerstein The biotech scorecard for the second quarter: 18 stock-moving events to watch
Health By Elizabeth Cooney ‘Drug development is a long, long process’: pharma CEO in Italy sounds a note of caution on Covid-19
Biotech By Adam Feuerstein and Matthew Herper Sage has a backup plan for its depression drug: Three new studies aiming for 2022 approval
Biotech By Adam Feuerstein Drug makers grounding salespeople as coronavirus impact on business spreads
Biotech By Damian Garde and Adam Feuerstein How one company made $208 million on an untested coronavirus vaccine
Business By Scott Kirsner — Boston Globe The Engine at MIT is revving up the potential of ‘tough tech’
Biotech By Jonathan Saltzman — Boston Globe Thermo Fisher buys Dutch diagnostics company for $11.5 billion
Biotech By Adam Feuerstein Biogen, Sangamo partner to develop genome-editing therapies for Alzheimer’s and Parkinson’s disease
Biotech By Adam Feuerstein With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption